Update of the drug resistance mutations in HIV-1: March 2013

Topics in Antiviral Medicine

Volumn 21, Issue 1, 2013, Pages 6-14

  Johnson, Victoria A ^a   Calvez, Vincent ^b   Günthard, Huldrych F ^c   Paredes, Roger ^d   Pillay, Deenan ^e   Shafer, Robert W ^f   Wensing, Annemarie M ^g   Richman, Douglas D ^h  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR PLUS RITONAVIR; INTEGRASE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE; RALTEGRAVIR; RILPIVIRINE; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CROSS RESISTANCE; DRUG RESPONSE; ENVELOPE GENE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; TREATMENT FAILURE;

ANTI-HIV AGENTS; DRUG RESISTANCE; HIV-1; HUMANS; MUTATION; VIRAL PROTEINS;

EID: 84877759801     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Clark SA, Shulman NS, Bosch RJ, Mellors JW. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS. 2006;20(7):981-984.
2. Picchio G, Vingerhoets J, Parkin N, Azijn H, de Bethune MP. Nucleoside-associated mutations cause hypersusceptibility to etravirine. [Abstract 23.] Antivir Ther. 2008;13(Suppl 3):A25.
3. Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA. Genetic correlates of efavirenz hypersusceptibility. AIDS. 2004;18(13):1781-1785.
4. Demeter LM, DeGruttola V, Lustgarten S, et al. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials. 2008;9(1):11-25.
5. Haubrich RH, Kemper CA, Hellmann NS, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002;16(15):F33-F40.
6. Tozzi V, Zaccarelli M, Narciso P, et al. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. J Infect Dis. 2004;189(9):1688-1695.
7. Katzenstein DA, Bosch RJ, Hellmann N, et al. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS. 2003;17(6):821-830.
8. von Wyl V, Ehteshami M, Demeter LM, et al. HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. Clin Infect Dis. 2010;51(5):620-628.
9. Gupta S, Vingerhoets J, Fransen S, et al. Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens. Antimicrob Agents Chemother. 2011;55(6):2872-2879.
10. Rimsky L, Van Eygen V, Vingerhoets J, Leijskens E, Picchio G. Reverse transcriptase connection domain mutations were not associated with virological failure or phenotypic resistance in rilpivirine-treated patients from the ECHO and THRIVE Phase III trials (week 96 analysis). [Abstract 28.] Antivir Ther. 2012;17:A36.
11. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189(5):837-846.
12. Whitcomb JM, Parkin NT, Chappey C, Hellman NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis. 2003;188(7):992-1000.
13. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989;246(4934):1155-1158.
14. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA. 1992;89(5):1934-1938.
15. Calvez V, Costagliola D, Descamps D, et al. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antivir Ther. 2002;7(3):211-218.
16. Kuritzkes DR, Bassett RL, Hazelwood JD, et al. Rate of thymidine analogue resistance mutation accumulation with zidovudine-or stavudine-based regimens. JAIDS. 2004;36(1):600-603.
17. Romano L, Venturi G, Bloor S, et al. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J Infect Dis. 2002;185(7):898-904.
18. Walter H, Schmidt B, Werwein M, Schwingel E, Korn K. Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrob Agents Chemother. 2002;46(1):89-94.
19. Mihailidis C, Dunn D, Pillay D, Pozniak A. Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy. AIDS. 2008;22(3):427-430.
20. Harrigan PR, Stone C, Griffin P, et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis. 2000;181(3):912-920.
21. Lanier ER, Ait-Khaled M, Scott J, et al. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir Ther. 2004;9(1):37-45.
22. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother. 1997;41(4):757-762. z1414.
23. Svarovskaia ES, Margot NA, Bae AS, et al. Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. JAIDS. 2007;46(2):174-180.
24. Marcelin AG, Flandre P, Pavie J, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother. 2005;49(5):1739-1744.
25. Molina JM, Marcelin AG, Pavie J, et al. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis. 2005;191(6):840-847.
26. Hawkins CA, Chaplin B, Idoko J, et al. Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. JAIDS. 2009;52(2):228-234.
27. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. JAIDS. 2010;53(4):480-484.
28. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS. 1996;10(9):975-981.
29. Violin M, Cozzi-Lepri A, Velleca R, et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS. 2004;18(2):227-235.
30. Chappey C, Wrin T, Deeks S, Petropoulos CJ. Evolution of amino acid 215 in HIV-1 reverse transcriptase in response to intermittent drug selection. [Abstract 32.] Antivir Ther. 2003;8:S37.
31. Garcia-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. J Virol. 2004;78(14):7545-7552.
32. Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS. 2007;21(11):1405-1414.
33. Parikh UM, Barnas DC, Faruki H, Mellors JW. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis. 2006;194(5):651-660.
34. von Wyl V, Yerly S, Böni J, et al. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis. 2008;46(8):1299-1309.
35. Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses. 2002;18(12):835-838.
36. Benhamida J, Chappey C, Coakley E, Parkin NT. HIV-1 genotype algorithms for prediction of etravirine susceptibility: novel mutations and weighting factors identified through correlations to phenotype. [Abstract 130.] Antivir Ther. 2008;13:A142.
37. Coakley E, Chappey C, Benhamida J, et al. Biological and clinical cut-off analyses for etravirine in the PhenoSense HIV assay. [Abstract 122.] Antivir Ther. 2008;13:A134.
38. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS. 2010;24(4):503-514.
39. Haddad M, Stawiski E, Benhamida J, Coakley E. Improved genotypic algorithm for predicting etravirine susceptibility: comprehensive list of mutations identified through correlation with matched phenotype. [Abstract 574.] 17th Conference on Retroviruses and Opportunistic Infections (CROI). February 16-19, 2010; San Francisco, CA.
40. Etravirine [package insert]. Bridgewater, NJ: Tibotec Therapeutics; 2008.
41. Scherrer AU, Hasse B, Von Wyl V, et al. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). HIV Med. 2009;10(10):647-656.
42. Tambuyzer L, Nijs S, Daems B, Picchio G, Vingerhoets J. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. JAIDS. 2011;58(1):18-22.
43. Tambuyzer L, Nijs S, Tomaka F, Picchio G, Vingerhoets J. Baseline and emerging resistance to etravirine in HIV-infected children and adolescents: final results from the Phase II PIANO Study. [Abstract 47.] Antivir Ther. 2012;17:A58.
44. Rilpivirine [package insert]. Titusville, NJ: Tibotec Pharmaceuticals; 2011.
45. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse tran scriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010;54(2):718-727.
46. Napolitano LA, Paquet AC, Petropoulos CJ, et al. Impact of genotypic mutations on phenotypic susceptibility to rilpivirine. [Abstract H1-371.] 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 17-20, 2011; Chicago, IL.
47. Haddad M, Napolitano LA, Paquet AC, et al. Impact of HIV-1 reverse transcriptase E138 mutations on rilpivirine drug susceptibility. [Abstract 10.] Antivir Ther. 2011;16:A18.
48. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378(9787):229-237.
49. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238-246.
50. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. JAIDS. 2012;59(1):39-46.
51. Kulkarni R, Babaoglu K, Lansdon EB, et al. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. JAIDS. 2012;59(1):47-54.
52. Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol. 2011;85(21):11309-11314.
53. Xu HT, Asahchop EL, Oliveira M, et al. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol. 2011;85(21):11300-11308.
54. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47(2):266-285.
55. Young TP, Parkin NT, Stawiski E, et al. Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease. Antimicrob Agents Chemother. 2010;54(11):4903-4906.
56. De Meyer S, Descamps D, Van Baelen B, et al. Confirmation of the negative impact of protease mutations I47V, I54M, T74P and I84V and the positive impact of protease mutation V82A on virological response to darunavir/ritonavir. [Abstract 126.] Antivir Ther. 2009;14:A147.
57. Descamps D, Lambert-Niclot S, Marcelin AG, et al. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother. 2009;63(3):585-592.
58. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007;15(4):119-125.
59. De Meyer S, Dierynck I, Lathouwers E, et al. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2. [Abstract 31.] Antivir Ther. 2008;13:A33.
60. Masquelier B, Breilh D, Neau D, et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2002;46(9):2926-2932.
61. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol. 2001;75(16):7462-7469.
62. Lopinavir/ritonavir [package insert]. Abbott Park, IL: Abbott Laboratories; 2010.
63. Mo H, King MS, King K, Molla A, Brun S, Kempf DJ. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir-and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol. 2005;79(6):3329-3338.
64. Friend J, Parkin N, Liegler T, Martin JN, Deeks SG. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS. 2004;18(14):1965-1966.
65. Kagan RM, Shenderovich M, Heseltine PN, Ramnarayan K. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci. 2005;14(7):1870-1878.
66. Gonzalez LM, Brindeiro RM, Aguiar RS, et al. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother. 2004;48(9):3552-3555.
67. Rhee SY, Taylor J, Fessel WJ, et al. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemo-ther. 2010;54(10):4253-4261.
68. Schapiro JM, Scherer J, Boucher CA, et al. Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. Antivir Ther. 2010;15(7):1011-1019.
69. Marcelin AG, Masquelier B, Descamps D, et al. Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2008;52(9):3237-3243.
70. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA. 2002;99(25):16249-16254.
71. Reeves JD, Miamidian JL, Biscone MJ, et al. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol. 2004;78(10):5476-5485.
72. Xu L, Pozniak A, Wildfire A, et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother. 2005;49(3):1113-1119.
73. Anastassopoulou CG, Ketas TJ, Sanders RW, Klasse PJ, Moore JP. Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. Virology. 2012;428(2):86-97.
74. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813-821.
75. Eron J, Livrozet JM, Morlat P, et al. Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961). J Int AIDS Soc. 2010;13(Suppl 4):O51.
76. Vavro CL, Dudas KC, Hasan S, Huang JO, Yeo JM, Underwood MR. Dolutegravir treatment of HIV subjects with raltegravir resistance: integrase resistance evolution in cohort II of the VIKING study. [Abstract 5.] Antivir Ther. 2012;Suppl 1.
77. Clotet B, Katlama C, Lalezari J, et al. HIV integrase resistance profiles and S/GSK1349572 baseline phenotypic susceptibility for individuals experiencing virologic failure on raltegravir and enrolling in the VIKING Phase IIb Pilot Study (ING112961). [Abstract 50.] 19th International HIV & Hepatitis Virus Resistance Workshop & Curative Strategies. June 8-12, 2010; Dubrovnik, Croatia.
78. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868)735-743.
79. Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013;207(5):740-748.
80. Hightower KE, DeAnda F, Wang R, Vavro CL, Underwood MR. Combinations of primary and secondary integrase mutations in the VIKING Pilot Study: effects on and rationale for dolutegravir dissociation. [Abstract 12.] 21st International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. June 5-9, 2012; Sitges, Spain.
81. Seki T, Kobayashi M, Miki S, et al. A high barrier to resistance for dolutegravir (DTG, S/GSK1349572) against raltegravir resistant Y143 mutants: an in vitro passage study. [Abstract 51.] 21st International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. June 5-9, 2012; Sitges, Spain.
82. Goodman D, Hluhanich R, Waters J, et al. Integrase inhibitor resistance involves complex interactions among primary and second resistance mutations: a novel mutation L68V/I associates with E92Q and increases resistance. [Abstract 13.] Antivir Ther. 2008;13:A15.
83. Waters J, Margot N, Hluhanich R, et al. Evolution of resistance to the HIV integrase inhibitor (INI) elvitegravir can involve genotypic switching among primary INI resistance patterns. [Abstract 116.] Antivir Ther. 2009;14:A137.
84. Geretti AM, Fearnhill E, Ceccherini-Silberstein F, et al. Prevalence and patterns of raltegravir resistance in treated patients in Europe. [Abstract 51.] Antivir Ther. 2010;159:A62.
85. Abram ME, Hluhanich RM, Goodman DD, et al. Effect of primary elvitegravir resistance mutations in HIV-1 integrase on drug susceptibility and viral replicative fitness. [Abstract 3.] Antivir Ther. 2012;17.
86. White KL, Kulkarni R, Szwareberg J, Quirk E, Cheng AK, Miles AJG. Integrated analysis of emergent drug resistance from the HIV-1 Phase 3 QUAD studies through week 48. [Abstract 4.] Antivir Ther. 2012;17:A11.
87. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439-2448.
88. DeJesus E, Rockstroh J, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379(9835):2429-2438.
89. Hazuda DF, Miller MD, Nguyen BY, Zhao J, for the P005 Study Team. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1 infection. Antivir Ther. 2007;12:S10.
90. Gatell JM, Katlama C, Grinsztejn B, et al. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. JAIDS. 2010;53(4):456-463.
91. Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol. 2009;83(22):11440-11446.
92. Hatano H, Lampiris H, Fransen S, et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2010;54(4):389-393.
93. Wittkop L, Breilh D, Da Silva D, et al. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. J Antimicrob Chemother. 2009;63(6):1251-1255.
94. Armenia D, Vandenbroucke I, Fabeni L, et al. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis. 2012;205(4):557-567.
95. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359(4):355-365.
96. Malet I, Delelis O, Valantin MA, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemo-ther. 2008;52(4):1351-1358.
97. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011;203(9):1204-1214.